Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant Candida albicans Isolates.

Literature DB >> 28483951

The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant Candida albicans Isolates.

Pilar Escribano^1,2, Laura Judith Marcos-Zambrano^3,2, Ana Gómez^3,2, Carlos Sánchez^3,2,4, M Carmen Martínez-Jiménez^3,2, Emilio Bouza^3,2,4,5, Jesús Guinea^1,2,4,5.

Abstract

We assessed the ability of the Etest performed directly on positive blood cultures (ETDIR) to detect fluconazole susceptibility in 6 fluconazole-resistant and 12 fluconazole-susceptible Candida albicans isolates, according to CLSI M27-A3 and EUCAST EDef 7.2 procedures. Categorical agreement between ETDIR and broth microdilution was 100% when the trays were incubated at 25°C and trailing effect was ruled out. ETDIR is a reliable procedure when screening for the presence of fluconazole resistance in C. albicans.

Entities: Chemical Species

Keywords: Candida albicans; Etest; fluconazole; resistance

Mesh：

Substances：

Year: 2017 PMID： 28483951 PMCID： PMC5487615 DOI： 10.1128/AAC.00400-17

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

43 in total

1. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors: Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal: Clin Infect Dis Date: 2006-05-16 Impact factor: 9.079

2. Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature.

Authors: D Agrawal; T F Patterson; M G Rinaldi; S G Revankar
Journal: J Med Microbiol Date: 2007-07 Impact factor: 2.472

3. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors: J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

4. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.

Authors: N Bourgeois; L Dehandschoewercker; S Bertout; P-J Bousquet; P Rispail; L Lachaud
Journal: J Clin Microbiol Date: 2009-11-04 Impact factor: 5.948

5. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors: O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal: Clin Microbiol Infect Date: 2012-12 Impact factor: 8.067

6. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors: Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191

7. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).

Authors: Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal: J Clin Microbiol Date: 2010-11-10 Impact factor: 5.948

8. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.

Authors: E Dannaoui; A Paugam; M Develoux; C Chochillon; J Matheron; A Datry; C Bouges-Michel; C Bonnal; F Dromer; S Bretagne
Journal: Clin Microbiol Infect Date: 2009-09-23 Impact factor: 8.067

9. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

Authors: Jesús Guinea; Óscar Zaragoza; Pilar Escribano; Estrella Martín-Mazuelos; Javier Pemán; Ferrán Sánchez-Reus; Manuel Cuenca-Estrella
Journal: Antimicrob Agents Chemother Date: 2013-12-23 Impact factor: 5.191

10. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence.

Authors: Andrea Lohberger; Alix T Coste; Dominique Sanglard
Journal: Eukaryot Cell Date: 2013-11-15

4 in total

1. Clinical Characteristics and Outcomes of Candidemia Caused by Meyerozyma guilliermondii Complex in Cancer Patients Undergoing Surgery.

Authors: Jingjing Chen; Sufei Tian; Fushun Li; Guoquan Sun; Ke Yun; Shitong Cheng; Yunzhuo Chu
Journal: Mycopathologia Date: 2020-09-28 Impact factor: 2.574